Claire J Garwood

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1730253/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Biological and methodological complexities of betaâ€amyloid peptide: Implications for Alzheimer's disease research. Journal of Neurochemistry, 2022, 160, 434-453.	2.1	12
2	Persistent DNA damage alters the neuronal transcriptome suggesting cell cycle dysregulation and altered mitochondrial function. European Journal of Neuroscience, 2021, 54, 6987-7005.	1.2	7
3	Amyloid binding and beyond: a new approach for Alzheimer's disease drug discovery targeting Aβo–PrP ^C binding and downstream pathways. Chemical Science, 2021, 12, 3768-3785.	3.7	6
4	Advanced Glycation End Product Formation in Human Cerebral Cortex Increases With Alzheimer-Type Neuropathologic Changes but Is Not Independently Associated With Dementia in a Population-Derived Aging Brain Cohort. Journal of Neuropathology and Experimental Neurology, 2020, 79, 950-958.	0.9	7
5	Glucosylpolyphenols as Inhibitors of Aβ-Induced Fyn Kinase Activation and Tau Phosphorylation: Synthesis, Membrane Permeability, and Exploratory Target Assessment within the Scope of Type 2 Diabetes and Alzheimer's Disease. Journal of Medicinal Chemistry, 2020, 63, 11663-11690.	2.9	17
6	Transcriptomic Analysis of Human Astrocytes In Vitro Reveals Hypoxia-Induced Mitochondrial Dysfunction, Modulation of Metabolism, and Dysregulation of the Immune Response. International Journal of Molecular Sciences, 2020, 21, 8028.	1.8	16
7	NDRG2 Expression Correlates with Neurofibrillary Tangles and Microglial Pathology in the Ageing Brain. International Journal of Molecular Sciences, 2020, 21, 340.	1.8	4
8	Discovery of <i>N</i> -methylpiperazinyl flavones as a novel class of compounds with therapeutic potential against Alzheimer's disease: synthesis, binding affinity towards amyloid β oligomers (Aβo) and ability to disrupt Aβo-PrP ^C interactions. Pure and Applied Chemistry, 2019, 91, 1107-1136.	0.9	10
9	Loss of IGF1R in Human Astrocytes Alters Complex I Activity and Support for Neurons. Neuroscience, 2018, 390, 46-59.	1.1	23
10	Proteomic and cellular localisation studies suggest nonâ€ŧight junction cytoplasmic and nuclear roles for occludin in astrocytes. European Journal of Neuroscience, 2018, 47, 1444-1456.	1.2	14
11	Metallothioneinâ€I/II expression associates with the astrocyte DNA damage response and not Alzheimerâ€type pathology in the aging brain. Glia, 2018, 66, 2316-2323.	2.5	27
12	Review: Astrocytes in Alzheimer's disease and other ageâ€associated dementias: a supporting player with a central role. Neuropathology and Applied Neurobiology, 2017, 43, 281-298.	1.8	166
13	Neuronal <scp>DNA</scp> damage responseâ€associated dysregulation of signalling pathways and cholesterol metabolism at the earliest stages of <scp>A</scp> lzheimerâ€type pathology. Neuropathology and Applied Neurobiology, 2016, 42, 167-179.	1.8	28
14	A Reduced Astrocyte Response to \hat{l}^2 -Amyloid Plaques in the Ageing Brain Associates with Cognitive Impairment. PLoS ONE, 2015, 10, e0118463.	1.1	45
15	The nuclear retention of transcription factor FOXO3a correlates with a DNA damage response and increased glutamine synthetase expression by astrocytes suggesting a neuroprotective role in the ageing brain. Neuroscience Letters, 2015, 609, 11-17.	1.0	58
16	Insulin and IGF1 signalling pathways in human astrocytes in vitro and in vivo; characterisation, subcellular localisation and modulation of the receptors. Molecular Brain, 2015, 8, 51.	1.3	68
17	A neuronal <scp>DNA</scp> damage response is detected at the earliest stages of <scp>A</scp> lzheimer's neuropathology and correlates with cognitive impairment in the <scp>M</scp> edical <scp>R</scp> esearch <scp>C</scp> ouncil's <scp>C</scp> ognitive <scp>F</scp> unction and <scp>A</scp> geing <scp>S</scp> tudy ageing brain cohort. Neuropathology	1.8	40
18	and Applied Neurobiology, 2015, 41, 465-496. Calpain cleavage and inactivation of the sodium calcium exchangerâ€3 occur downstream of <scp>A</scp> l² in <scp>A</scp> lzheimer's disease. Aging Cell, 2014, 13, 49-59.	3.0	38

CLAIRE J GARWOOD

#	Article	IF	CITATIONS
19	<pre><scp>DNA</scp> damage response and senescence in endothelial cells of human cerebral cortex and relation to <scp>A</scp>lzheimer's neuropathology progression: a populationâ€based study in the <scp>M</scp>edical <scp>R</scp>esearch <scp>C</scp>ouncil <scp>C</scp>ognitive <scp>F</scp>unction and <scp>A</scp>geing <scp>S</scp>tudy (<scp>MRC</scp>â€<scp>CFAS</scp>)</pre>	1.8	30
20	Astrocytes and neuroinflammation in Alzheimer's disease. Biochemical Society Transactions, 2014, 42, 1321-1325.	1.6	76
21	Alterations in the blood brain barrier in ageing cerebral cortex in relationship to Alzheimer-type pathology: A study in the MRC-CFAS population neuropathology cohort. Neuroscience Letters, 2011, 505, 25-30.	1.0	90
22	Microarray analysis of the astrocyte transcriptome in the aging brain: relationship to Alzheimer's pathology and APOE genotype. Neurobiology of Aging, 2011, 32, 1795-1807.	1.5	166
23	Anti-Inflammatory Impact of Minocycline in a Mouse Model of Tauopathy. Frontiers in Psychiatry, 2010, 1, 136.	1.3	91
24	Minocycline as a potential therapeutic agent in neurodegenerative disorders characterized by protein misfolding. Prion, 2009, 3, 78-83.	0.9	59
25	Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. FASEB Journal, 2009, 23, 739-750.	0.2	113
26	Phosphorylation Regulates Tau Interactions with Src Homology 3 Domains of Phosphatidylinositol 3-Kinase, Phospholipase Cl̂ ³ 1, Grb2, and Src Family Kinases. Journal of Biological Chemistry, 2008, 283, 18177-18186.	1.6	198
27	Kinase activities increase during the development of tauopathy in htau mice. Journal of Neurochemistry, 2007, 103, 2256-2267.	2.1	69